Trending Topic

< 1 min

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text. In the section “Eplontersen”, the administration schedule should be written as […]

Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock and Hyperkalemia Syndrome Involving Digoxin Toxicity: A Case Report

Meet Shah, Arthi Palani, Ashkan Hashemi, Jaewook Shin
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Jun 8th 2023 Heart International. 2023;17(1):60–2 DOI: https://doi.org/10.17925/HI.2023.17.1.60
Select a Section…
1

Abstract

Overview

Bradycardia, renal failure, a sand h (BRASH) syndrome is named after the pentad of symptoms experienced by patients with this clinical entity, and is propagated via a synergistic mechanism. Herein, we describe a case of an 81-year-old male who presented with bradycardia, dyspnoea on exertion, and confusion. He was also initially found to be in cardiogenic shock. In a setting of elevated digoxin levels, acute renal failure and hyperkalemia, he was diagnosed with BRASH syndrome. Prompt interventions of continuous renal replacement therapy and digoxin antibody administration were performed to treat this patient. His renal function improved and his hyperkalemia and bradycardia resolved over the course of 4 days, and the patient was discharged to a subacute rehabilitation facility after stabilization. BRASH syndrome is a clinical entity requiring prompt diagnosis for life-saving treatment, including renal replacement therapy, vasoactive medications, transvenous pacing, and reversing agents, when appropriate.

Keywords

Atrioventricular block, bradycardia, BRASH, cardiogenic shock, case report, digoxin, hyperkalemia, renal failure

2

Article

Bradycardia, renal failure, atrioventricular nodal blockade, shock and hyperkalemia (BRASH) syndrome is a rare, often unrecognized but potentially life-threatening clinical entity that is characterized by the pentad of symptoms after which it is named. BRASH syndrome is seen most commonly in the setting of atrioventricular nodal-blocking medications such as beta-blockers and calcium channel blockers.1,2

The synergistic interplay of low cardiac output state, renal function and high potassium creates a vicious cycle that can escalate quickly. Hyperkalemia can cause bradycardia, which can lead to low cardiac output and poor renal function. As the kidneys are unable to clear potassium from the bloodstream effectively, this can exacerbate hyperkalemia. Hyperkalemia in the setting of atrioventricular nodal-blocking agents can further impair electrical signalling in the heart, which can progress to cardiogenic shock, cardiac arrest and, ultimately, death.3

Given the potential consequences of BRASH syndrome, and its often rapid course, a thorough understanding of the underlying mechanisms and clinical context is necessary for improving patient outcomes and reducing the risk of associated serious adverse events. Across the literature, there remains a variety of clinical presentations, precipitating factors and treatment methods, indicating the need for further study.4

This case report represents an uncommon presentation of bradycardia, renal failure, atrioventricular nodal blockade, shock and persistent hyperkalemia that was refractory to conservative management, in the setting of digoxin toxicity.

Compliance with ethics

Ethics approval was not required for this case report, as it was deemed not to constitute research, by the Rutgers Institutional Review Board. This research was a retrospective chart review study and is not subject to institutional review board approval. The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. Verbal consent was obtained from the patient for this case study by the primary medical team. The verbal consent was obtained by the primary medical team over the telephone after the patient was discharged to the rehabilitation facility. Due to the patient being at the facility, obtaining a written consent was deferred and the patient was assured that no patient identifying information would be used for any research reports. No identifying patient information is included in this manuscript.

Case presentation

An 81-year-old male presented to an outpatient appointment with progressive dyspnoea on exertion, confusion and abdominal distention, all which began a few days prior to the appointment. He had a past medical history of hypertension, type 2 diabetes mellitus, heart failure with preserved ejection fraction (ejection fraction of 58%), atrial fibrillation on apixaban and digoxin, mitral regurgitation, tricuspid regurgitation, lung cancer, and right middle and lower lobectomy. At the doctor’s office, the patient was found to be bradycardic (25 beats per minute [bpm]) with a blood pressure of 85/38 mmHg. The doctor referred the patient to the emergency room, and en route, 1 mg of intravenous atropine was administered for bradycardia, resulting in an improvement of heart rate to 40 bpm. Laboratory results on arrival in the emergency department were notable for potassium level of 6.9 mMol/L, creatinine level of 3.10 (baseline 0.7), and digoxin level of 2.7 ng/mL. The electrocardiogram showed wide complex bradycardia and ventricular rate of 48 bpm, with a left bundle branch block morphology (Figure 1). The patient was given a 2 L fluid bolus and was started on dopamine drip for bradycardia and hypotension. For his hyperkalemia, he was treated with 1 g intravenous calcium gluconate, and 10 units of intravenous insulin and dextrose-50. In the setting of elevated digoxin levels and acute renal failure, digoxin was discontinued and 2 vials of digoxin antibody (DigiFab®BTG International Inc.Conshohocken, PA, USA), 40 mg each, were administered to the patient. Subsequent laboratory results after the initial interventions showed that his potassium levels remained elevated at 6.7 mMol/L. A clinical decision was made to start continuous renal replacement therapy (CRRT) in the setting of acute renal failure. In the subsequent days, his blood pressure, bradycardia, and mentation progressively improved, and he was weaned from the dopamine drip. The patient was also weaned from the CRRT treatment after 4 days, and his kidneys appropriately responded to an intravenous furosemide challenge, with 2.5 L of urine output. On the sixth day after admission, the patient developed aspiration pneumonia, for which he was treated with 4.5 g of piperacillin-tazobactam intravenous antibiotics, every six hours for five days. Ten days after admission, he was eventually discharged to a subacute rehabilitation facility.

Discussion

Recognizing BRASH syndrome and differentiating it from isolated hyperkalemia-induced arrythmias is an important step in clinical decision-making, and management of a patient that presents with this clinical entity. Calcium channel blockers and beta-blockers have been recognized as pharmacologic agents associated with BRASH syndrome in the literature.5,6 However, digoxin-associated BRASH syndrome has not been widely reported. Management of this clinical entity can include interventions to correct any or all five of its symptoms. Initial stabilization with calcium gluconate, insulin/glucose, transvenous pacemaker, vasopressor medications, and haemodialysis are mainstay treatments reported in the literature.7–9 The patient in this case was initially treated with fluid resuscitation and dopamine to manage his shock. He was also simultaneously treated with insulin and glucose to correct hyperkalemia. Digoxin was withheld, as it contributed to the synergistic mechanism of BRASH syndrome, and digoxin antibody was administered to reverse the digoxin toxicity. Soon thereafter, a clinical decision was made to start CRRT in the patient, as his acute renal failure had not improved with the given interventions. The limitations of this case are that generalization of BRASH syndrome management cannot be made as it is patient-centered, and the treatment outlined here may vary from case to case as there are no consolidated treatment guidelines in the literature.

As seen in this patient, multiple medical interventions are required in a timely manner to stop the synergistic mechanism involved in BRASH syndrome. Since the decision for haemodialysis was concerning, due to shock, CRRT was pursued as an alternative to correct hyperkalemia and acute renal failure. This case demonstrates that early and aggressive interventions are lifesaving when there is a high index of suspicion for BRASH syndrome.

3

References

List View
Grid View
1
Copy URLURL Copied
Visit URL

 Lizyness KDewald OBRASH syndromeInStatPearls [Internet]Treasure Island (FL)StatPearls Publishing2022. Available atwww.ncbi.nlm.nih.gov/books/NBK570643

2
Copy DOIDOI Copied
Visit DOI Link

 Arif AWKhan MSMasri Aet alBRASH syndrome with hyperkalemia: An under-recognized clinical condition. Methodist Debakey Cardiovasc J2020;16:2414DOI10.14797/mdcj-16-3-241

3
Copy DOIDOI Copied
Visit DOI Link

 Farkas JDLong BKoyfman AMenson KBRASH syndrome: Bradycardia, renal failure, AV blockade, shock, and hyperkalemiaJ Emerg Med2020;59:21623DOI10.1016/j.jemermed.2020.05.001

4
Copy DOIDOI Copied
Visit DOI Link

 Shah PGozun MKeitoku Ket alClinical characteristics of BRASH syndrome: Systematic scoping reviewEur J Intern Med2022;103:5761DOI10.1016/j.ejim.2022.06.002

5
Copy DOIDOI Copied
Visit DOI Link

 Al-Khafaji MAl-Salem IHNifedipine induced bradycardia in a patient with autonomic neuropathyJpn Heart J1989;30:67983DOI10.1536/ihj.30.679

6
Copy DOIDOI Copied
Visit DOI Link

 Simmons TBlazar ESynergistic bradycardia from beta blockers, hyperkalemia, and renal failureJ Emerg Med2019;57:e414DOI10.1016/j.jemermed.2019.03.039

7
Copy DOIDOI Copied
Visit DOI Link

 Srivastava SKemnic THildebrandt KRBRASH syndromeBMJ Case Rep2020;13:e233825. DOI10.1136/bcr-2019-233825.

8
Copy DOIDOI Copied
Visit DOI Link

 Majeed HKhan UKhan AMet alBRASH syndrome: A systematic review of reported casesCurr Probl Cardiol. 2023;48:101663DOI10.1016/j.cpcardiol.2023.101663.

9
Copy DOIDOI Copied
Visit DOI Link

 Bailuni Neto JJSiqueira B de LMachado FCet alBRASH syndrome: A case reportAm J Case Rep2022;23:e934600DOI10.12659/AJCR.934600.

4

Article Information

Disclosure

Meet Shah, Arthi Palani, Ashkan Hashemi and Jaewook Shin have no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

Ethics approval was not required for this case report, as it was deemed not to constitute research, by the Rutgers Institutional Review Board. This research was a retrospective chart review study and is not subject to institutional review board approval. The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. Verbal consent was obtained from the patient for this case study by the primary medical team. The verbal consent was obtained by the primary medical team over the telephone after the patient was discharged to the rehabilitation facility. Due to the patient being at the facility, obtaining a written consent was deferred and the patient was assured that no patient identifying information would be used for any research reports. No identifying patient information is included in this manuscript.

Review Process

Double-blind peer review.

Authorship

The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Correspondence

Meet Shah, Rutgers New Jersey Medical School, 150 Bergen Street, I-248 Newark, NJ 07103, USA. E: mshah961@gmail.com

Support

No funding was received in the publication of this article.

Access

This article is freely accessible at touchCARDIO.com ©Touch Medical Media 2023

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.

Received

2023-03-05

5

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup